Recurrent Atrial Fibrillation Market Growth – at a CAGR of 13.2% by 2028

Rising prevalence of heart disease across the globe and increasing focus on development of personalized drugs & therapeutics are among the key factors driving the global Recurrent Atrial Fibrillation market revenue growth.

Emergen Research has published its latest report titled “Recurrent Atrial Fibrillation Market, By Product Type (Devices, Drugs), By Application (EP Ablation, Diagnostics, Cardiac Surgery), By End-use (Hospitals, Ambulatory Surgical Centers, Cardiac Centers), and By Region Forecast to 2028”

According to Emergen Research, the global recurrent atrial fibrillation market size was USD 10.76 billion in 2020 and is expected to reach USD 29.35 billion in 2028 and register a revenue CAGR of 13.2% during the forecast period, 2021-2028.

Market Dynamics:

Steady revenue growth of the global recurrent atrial fibrillation market is attributed to factors such as rapidly growing geriatric population, rising prevalence of cardiovascular diseases such as stroke, heart failure, and atrial fibrillation worldwide, increasing cases of recurrent atrial fibrillation, and rising burden of chronic disorders such as sleep apnea, hypertension, stress, obesity, thyroid disorders, and lung disease. Rising focus on development of personalized drugs & therapeutics for treatment of atrial fibrillation, launch of new and more advanced treatment options, technological advancements in devices for atrial fibrillation (Afib), and increasing availability of better reimbursement plans & policies for recurrent Afib medications are some of the other major factors expected to drive the global recurrent atrial fibrillation market revenue growth over the forecast period.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@

In addition, factors such as rising caseload of the novel coronavirus infection around the globe, growing susceptibility of patients infected with COVID-19 to atrial fibrillation and cardiac arrhythmia, increasing awareness of early diagnosis and treatment of heart disease, and increasing volumes of diagnostic tests including EKG and ECG further drive the global market growth. According to a study by the CDC, over 6.1 million people in the U.S. are currently affected by Afib, and the figure is expected to surpass 12.1 million by 2030.

COVID-19 Impact Analysis:

  • Social distancing and restrictions severely disrupted businesses and operations
  • Lockdowns caused disruptions in transportation and logistics
  • Impacted manufacturing activities and mining operations globally
  • Took a toll on economy of various countries
  • Caused sudden and drastic downturn in economic activity
  • Disrupted agriculture, fisheries, dairy, and other sectors
  • Caused loss of employment and financial crisis
  • Supply impacts were further compounded owing to reduced disposable income
  • Emergence of variants  continue to cause concerns and impact normal routines

Devices Segment Accounted for Largest Revenue Share in 2020:

Based on product type, the devices segment dominated other segments in terms of revenue share in the global recurrent atrial fibrillation market in 2020. Growing prevalence of cardiovascular diseases such as stroke, atrial fibrillation, and cardiac arrhythmia, rising need for more advanced treatment options for atrial fibrillation, increasing volumes of cardiac surgeries, and increasing usage of advanced Afib devices, such as electrophysiology (EP) ablation catheters, EP diagnostic catheters, laser-based catheter ablation devices, and intracardiac echocardiography (ICE) systems, are key factors driving this segment’s revenue growth.

Buy Your Copy Now (Customized Report Delivered as per Your Specific Requirement)@

EP Ablation Segment to Account for Fastest Revenue CAGR:

Based on application, the global recurrent atrial fibrillation market is segmented into EP ablation, diagnostics, and cardiac surgery. The EP ablation segment is expected to register the fastest revenue growth rate in the global market over the forecast period. Electrophysiology ablation is a procedure that assesses the electrical activity of the heart and helps in the treatment of cardiac arrhythmia, atrial fibrillation, and other heart diseases. Increasing use of EP ablation devices and technological advances in atrial fibrillation treatment devices are major factors driving revenue growth of this segment.

North America Accounted for Largest Revenue Share in 2020:

Among regional markets, the North America recurrent atrial fibrillation market led in terms of largest revenue share in the global market in 2020. Some of the major factors boosting the North America market revenue growth are growing prevalence of cardiovascular diseases, increasing incidences of recurrent Afib, rapid adoption of personalized Afib drugs & therapeutics, development of highly advanced, software-based ECG monitoring devices for improved treatment of recurrent AFib patients, and presence of avant-garde healthcare infrastructure in the region.

Major Companies in the Global Recurrent Atrial Fibrillation Market Include:

  • GlaxoSmithKline
  • Johnson & Johnson
  • Abbott Laboratories
  • St. Jude Medical, Inc.
  • Atricure Inc.
  • Boston Scientific Corporation
  • Medtronic Plc
  • Boehringer Ingelheim
  • Siemens AG
  • Daiichi Sankyo
  • Koninklijke Philips N.V.
  • AstraZeneca
  • Bristol-Myers Squibb Inc.
  • Microport Scientific Corporation

For the purpose of this report, Emergen Research has segmented the global recurrent atrial fibrillation market on the basis of product type, application, end-use, and region:

Product Type Outlook (Revenue, USD Billion; 2018-2028)

  • Devices
  • Surgical Devices
  • Maze Surgery
  • Catheter Ablation
  • Radiofrequency Catheter Ablation
  • Conventional RF Ablation Catheters
  • Irrigated-tip RF Ablation Catheters
  • Cryoablation
  • Microwave-based Catheter Ablation
  • Laser-based Catheter Ablation
  • Navigational Advanced Mapping Accessories
  • Non-surgical Devices
  • Electric Cardioversion
  • EP Ablation Catheters
  • EP Diagnostic Catheter
  • Conventional Diagnostic Catheters
  • Fixed Diagnostic Catheters
  • Steerable Diagnostic Catheters
  • Advanced Diagnostic Catheters
  • Mapping and Recording Systems
  • Cardiac Monitors or Loop Recorders
  • Access Devices
  • Left Atrial Appendage and Closure Devices
  • Intracardiac Echocardiography (ICE) Systems
  • Drugs
  • Dabigatran (Pradaxa)
  • Rivaroxaban (Xarelto)
  • Apixaban (Eliquis)
  • Edoxaban (Savaysa)
  • Warfarin (Coumadin)
  • Others

Application Outlook (Revenue, USD Billion; 2018-2028)

  • EP Ablation
  • Diagnostics
  • Cardiac Surgery

End-use Outlook (Revenue, USD Billion; 2018-2028)

  • Hospitals
  • Cardiac Centers
  • Ambulatory Surgical Centers

Click on the link to read key highlights of the report and look at projected trends for years to come:

Region Outlook (Revenue, USD Billion; 2018-2028)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Saudi Arabia
    • U.A.E.
    • South Africa
    • Turkey
    • Rest of Middle East & Africa

Latest Published Reports by Emergen Research:

Xanthan Gum Market By Form (Liquid, Dry), By Application (Stabilizer, Thickener, Gelling Agent, Coating Material, Fat Replacer), By Industry Vertical (Food & Beverages, Pharmaceutical, Oil & Gas, Cosmetic & Personal Care), and By Region Forecast to 2028.

Lightweight Materials Market, By Product Type (Plastics, Metals, Composites, Elastomers), By Distribution Channel (Direct, Indirect), By Application (Automotive, Aerospace, Energy, Marine), and By Region Forecast to 2028.

Biorational Product Market, By Type (Insecticides, Fungicides, and Nematicides), By Source (Botanical, Microbial, and Non-Organic), By Mode of Application (Foliar Spray, Soil treatment, and Trunk Injection), and By Region Forecast to 2028.

Optically Clear Adhesive Market By Resin Type (Polyvinyl Acetate, Acrylic, Polyurethane, Epoxy, Silicone, Others), Device Structure, Substrate, Application (Mobile Phones, Monitors & Laptop, Others), By End-Use, and By Region Forecast to 2028.

Metal Foam Market By Material (Aluminum, Copper, Titanium, Zinc, Nickel), By Product (Open Cell, Closed Cell), By Application (Floating Cities, Heat Exchangers, Anti-Intrusion Bars, Energy Absorbers), By End-Use, and By Region Forecast to 2028.

Fullerene Market By Type (C60, C70, C76, Other), By Production Method (Arc Discharge Method, CVD/CCVD Process, Laser Ablation of Graphite, Others), By Shape (Nanotubes, Bucky Balls, Nano-Rods), By End-use, and By Region Forecast to 2028

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web:

Direct Line: +1 (604) 757-9756


Visit for More Insights:

Explore Our Custom Intelligence services | Growth Consulting Services

Read Press Release@
















Back to news